Arena Pharamceuticals Down on Experimental Drug’s Safety Concerns

Jacob Harper |

Cult biotech stock Arena Pharmaceuticals Inc. ($ARNA) was dealt a major blow on Aug. 29 when the company’s experimental lung drug APD811 encountered a major stumbling block. The drug, intended to treat pulmonary arterial hypertension, was supposed to progress to mid-stage trials in early 2014. However, a patient taking the drug experienced unexpected heart complications, seriously damaging the drug’s development from progressing further.

Still, the company has its share of vocal proponents. Jim Cramer said the company’s anti-obesity drug Belviq is “the best on the market” and recommended it for a speculative play. Arena bulls were further bolstered on Aug. 5, when the company released an earnings report that exceeded expectations.



Arena had first begun to gain major momentum on June 20 when  the American Medical Association classified obesity as a “disease,” opening up the possibility for their anti-obesity drug Belviq to be covered under insurance plans. The success of Belviq was a major factor in the company’s healthy Q2 2013 earnings.

Besides their flagship drug Belviq and APD811, the company has two other drugs in clinical trials – an autoimmune disease drug and one designed to treat blood clot disorders.

Despite the biotech’s popularity with some investors and analysts, the stock has its doubters further bolstered by the setback for APD811. Of eight analysts reporting recommendations for Arena, four have a “hold” and one firm, Credit Suisse, puts the stock at “underperform.”  

The stock is down 5.23 percent to hit $6.34, and down 25.75 percent on the year.

 

(image of laboratory courtesy of WIkimedia Commons)

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Companies

Symbol Name Price Change % Volume
ARNA Arena Pharmaceuticals Inc. 1.39 0.03 1.84 1,144,613 Trade
OMDHF One Media Holdings Plc n/a n/a n/a 0

Comments

Emerging Growth

GSV Capital Corp

GSV Capital Corp is an externally managed, non-diversified closed-end management investment company. The Company has elected to be treated as a business development company.

Private Markets

Trustify

Trustify provides trust and safety in both the digital and physical worlds through our vast network of on-demand Private Investigators.By removing the large retainers and high hourly rates that traditional…

Quants Inc

Quants, Inc, a California Corporation, develops, markets and operates financial technology platforms and alternative investment products offering sophisticated risk management since 2010. The Company has primarily sharpened its focus with…